Web Desc
Cancer Evolution and Combinatorial Cancer Therapies: Concepts and Challenges
Scientific Organizers: William Sellers, Charles Swanton and Lillian Siu
Date: January 19 - 23, 2020
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by BioLegend, Inc., Incyte Corporation, Novartis Institutes for BioMedical Research and Roche
Summary of Meeting:
Progress in understanding the clonal and sub-clonal processes driving tumor evolution, tumor heterogeneity, the mechanisms of therapeutic resistance, and in defining new cancer dependencies have converged to help inform more rational approaches to achieving the development of transformative combination therapeutic regimens in cancer. Nonetheless, examples of highly effective rationally elucidated combinations remain rare and the pre-clinical and clinical development challenges to this goal are substantial. As an example, the emergent role of immunotherapeutics having curative potential has led to tremendous excitement, yet increased complexity. The broad swath of empiric based clinical trials attests to the continued and growing need for improved pre-clinical means by which transformative combinations can be identified. This conference will bring together evolutionary and computational biologists, experts in functional genomics, translational scientists, drug discovery researchers and physician leaders in clinical development. The conference program begins with how evolutionary processes drive the “natural” progression of cancer and how such processes lead to the measured heterogeneous populations of cells resident in all tumors. These two related forces, driven at least in part by ongoing mutational processes, then combine to give rise to therapeutic resistance, which enables researchers to robustly identify mechanisms relevant to humans in pre-clinical models. The deeper understanding of these forces can inform specific combination therapeutics, but combination hypotheses are now being discovered though genome-scale functional screening approaches (e.g. CRISPR, shRNA). Speakers have been invited to discuss the studies which are now taking place in both the targeted and immuno-oncology (I/O) therapeutic fields. These talks filter into sessions on understanding how I/O and targeted therapeutics are similar or distinct and to seek the lessons from the clinical trial outputs in the I/O field that will emerge over the next year. Finally, clinical development paradigms for more rapidly testing and developing combinations will be covered during the conference.
DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: September 25 2019 details
Discounted Abstract Deadline: September 25 2019 details & pricing
Abstract Deadline: October 17 2019 details & pricing
Discounted Registration Deadline: November 20 2019 details & pricing


Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.


Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.


Keystone Symposia thanks our Sponsor for generously supporting this meeting:
BioLegend, Inc.Incyte CorporationNovartis Institutes for BioMedical ResearchRoche
We gratefully acknowledge additional support from these exhibitors at this conference:
American Association for Cancer Research (AACR)Myriad-RBM
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Incyte Corporation
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found